Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan: Complete Statistical AnalysisIndependent statistical analysis of ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ONPEDIndependent statistical analysis of Oral Naltrexone In Pediatric Eating Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073679).
- onset 9Independent statistical analysis of onset 9, a randomized phase 3 trial comparing faster-acting insulin aspart with NovoRapid in people with type 2 diabetes, including its non-inferiority analysis of HbA1c change.
- onset 9Independent statistical analysis of Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes: primary endpoint results, effect estimate with confidence…
- ONTAKIndependent statistical analysis of A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ONTARGETAn independent statistical analysis of ONTARGET and its companion trial TRANSCEND: Cox hazard ratios for telmisartan, ramipril and their combination, the non-inferiority margin of 1.13, renal outcomes in diabetic nephropathy, and serious…
- Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ONWARDIndependent statistical analysis of A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD): primary endpoint results, effect estimate with confidence interval,…
- ONWARDS 5Independent statistical analysis of A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used…
- ONYXIndependent statistical analysis of Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection: primary endpoint results, effect estimate…
- Onyx ONE ClearIndependent statistical analysis of A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear): primary endpoint results, effect estimate with…
- Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04467840).
- OPAL BEYONDIndependent statistical analysis of Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OPALINEIndependent statistical analysis of OPALINE : A Study Of Morbidity And Mortality At 2 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis: Complete Statistical AnalysisIndependent statistical analysis of OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: Complete Statistical AnalysisIndependent statistical analysis of Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: primary endpoint results, effect estimate with…
- Open Hemorrohoidectomy Vs Transanal Hemorrhoidal Desarterialization in Hemorrhoids Grade III: The Effect on Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Open Hemorrohoidectomy Vs Transanal Hemorrhoidal Desarterialization in Hemorrhoids Grade III: The Effect on Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl: Complete Statistical AnalysisIndependent statistical analysis of Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open Label Extension In Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension In Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00830180).
- Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD: Complete Statistical AnalysisIndependent statistical analysis of Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel: Complete Statistical AnalysisIndependent statistical analysis of Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02946788).
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): primary endpoint results, effect estimate with confidence…
- Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00901342).
- Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open Label Study Telmisartan and Amlodipine in Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study Telmisartan and Amlodipine in Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00614380).
- Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with…
- Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: Complete Statistical AnalysisIndependent statistical analysis of Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact: Complete Statistical AnalysisIndependent statistical analysis of Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact: primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-label Extension for Phase 3 Clinical Trials of Simufilam: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension for Phase 3 Clinical Trials of Simufilam: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05575076).
- Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05459688).
- Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Open-Label Extension Study of Trofinetide for Rett Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Trofinetide for Rett Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04776746).
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…